Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 May;62(5):423–426. doi: 10.1136/ard.62.5.423

Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis

M Hoekstra 1, A E van Ede 1, C Haagsma 1, M A F J van de Laar 1, T Huizinga 1, M Kruijsen 1, R Laan 1
PMCID: PMC1754533  PMID: 12695153

Abstract

Objective: To study factors associated with toxicity, final dose, and efficacy of methotrexate (MTX) in patients with rheumatoid arthritis (RA).

Methods: Data were used from a randomised clinical 48 week trial on 411 patients with RA all treated with MTX, comparing folates and placebo. Logistic regression was used to study the relation between baseline variables and various dependent factors, including hepatotoxicity (alanine aminotransferase ⩾3xupper limit of normal), MTX withdrawal, final MTX dose ⩾15 mg/week, and MTX efficacy.

Results: Addition of folates to MTX treatment was strongly related to the lack of hepatotoxicity. Next to this, high body mass index was related to the occurrence of hepatotoxicity. Prior gastrointestinal (GI) events and younger age were related to the adverse event, diarrhoea. Hepatotoxicity and GI adverse events were the main reason for MTX withdrawal, which in turn was associated with the absence of folate supplementation, body mass index, prior GI events, and female sex. Renal function (creatinine clearance ⩾50 ml/min) was not associated with toxicity. Reaching a final dose of MTX of ⩾15 mg/week was related to folate supplementation and the absence of prior GI events. Efficacy of MTX treatment was associated with low disease activity at baseline, male sex, use of non-steroidal anti-inflammatory drugs (NSAIDs), and lower creatinine clearance.

Conclusions: MTX toxicity, final dose, and efficacy are influenced by folate supplementation. Baseline characteristics predicting the outcome of MTX treatment are mainly prior GI events, body mass index, sex, use of NSAIDs, and creatinine clearance.

Full Text

The Full Text of this article is available as a PDF (108.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón G. S., Kremer J. M., Macaluso M., Weinblatt M. E., Cannon G. W., Palmer W. R., St Clair E. W., Sundy J. S., Alexander R. W., Smith G. J. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997 Sep 1;127(5):356–364. doi: 10.7326/0003-4819-127-5-199709010-00003. [DOI] [PubMed] [Google Scholar]
  2. Alarcón G. S., Tracy I. C., Blackburn W. D., Jr Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum. 1989 Jun;32(6):671–676. doi: 10.1002/anr.1780320603. [DOI] [PubMed] [Google Scholar]
  3. Anderson J. J., Wells G., Verhoeven A. C., Felson D. T. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000 Jan;43(1):22–29. doi: 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  4. Bologna C., Viu P., Jorgensen C., Sany J. Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Br J Rheumatol. 1996 May;35(5):453–457. doi: 10.1093/rheumatology/35.5.453. [DOI] [PubMed] [Google Scholar]
  5. Bologna C., Viu P., Picot M. C., Jorgensen C., Sany J. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol. 1997 May;36(5):535–540. doi: 10.1093/rheumatology/36.5.535. [DOI] [PubMed] [Google Scholar]
  6. Brick J. E., Moreland L. W., Al-Kawas F., Chang W. W., Layne R. D., DiBartolomeo A. G. Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. Semin Arthritis Rheum. 1989 Aug;19(1):31–44. doi: 10.1016/0049-0172(89)90085-1. [DOI] [PubMed] [Google Scholar]
  7. Carroll G. J., Thomas R., Phatouros C. C., Atchison M. H., Leslie A. L., Cook N. J., D'Souza I. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol. 1994 Jan;21(1):51–54. [PubMed] [Google Scholar]
  8. Carson C. W., Cannon G. W., Egger M. J., Ward J. R., Clegg D. O. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum. 1987 Feb;16(3):186–195. doi: 10.1016/0049-0172(87)90021-7. [DOI] [PubMed] [Google Scholar]
  9. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  10. Cush J. J., Lipsky P. E., Postlethwaite A. E., Schrohenloher R. E., Saway A., Koopman W. J. Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis. Arthritis Rheum. 1990 Jan;33(1):19–28. doi: 10.1002/art.1780330103. [DOI] [PubMed] [Google Scholar]
  11. Felson D. T., Anderson J. J., Meenan R. F. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum. 1990 Oct;33(10):1449–1461. doi: 10.1002/art.1780331001. [DOI] [PubMed] [Google Scholar]
  12. Furst D. E., Koehnke R., Burmeister L. F., Kohler J., Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol. 1989 Mar;16(3):313–320. [PubMed] [Google Scholar]
  13. Golden M. R., Katz R. S., Balk R. A., Golden H. E. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol. 1995 Jun;22(6):1043–1047. [PubMed] [Google Scholar]
  14. Gutierrez-Ureña S., Molina J. F., García C. O., Cuéllar M. L., Espinoza L. R. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996 Feb;39(2):272–276. doi: 10.1002/art.1780390214. [DOI] [PubMed] [Google Scholar]
  15. Hanrahan P. S., Russell A. S. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol. 1988 Jul;15(7):1078–1080. [PubMed] [Google Scholar]
  16. Kremer J. M., Lee R. G., Tolman K. G. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum. 1989 Feb;32(2):121–127. doi: 10.1002/anr.1780320202. [DOI] [PubMed] [Google Scholar]
  17. Kremer J. M., Phelps C. T. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 1992 Feb;35(2):138–145. doi: 10.1002/art.1780350203. [DOI] [PubMed] [Google Scholar]
  18. McKendry R. J., Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol. 1993 Nov;20(11):1850–1856. [PubMed] [Google Scholar]
  19. Morgan S. L., Baggott J. E., Vaughn W. H., Austin J. S., Veitch T. A., Lee J. Y., Koopman W. J., Krumdieck C. L., Alarcón G. S. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994 Dec 1;121(11):833–841. doi: 10.7326/0003-4819-121-11-199412010-00002. [DOI] [PubMed] [Google Scholar]
  20. Morgan S. L., Baggott J. E., Vaughn W. H., Young P. K., Austin J. V., Krumdieck C. L., Alarcón G. S. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990 Jan;33(1):9–18. doi: 10.1002/art.1780330102. [DOI] [PubMed] [Google Scholar]
  21. Ohosone Y., Okano Y., Kameda H., Fujii T., Hama N., Hirakata M., Mimori T., Akizuki M., Ikeda Y. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol. 1997 Dec;24(12):2299–2303. [PubMed] [Google Scholar]
  22. Seideman P. Methotrexate--the relationship between dose and clinical effect. Br J Rheumatol. 1993 Aug;32(8):751–753. doi: 10.1093/rheumatology/32.8.751. [DOI] [PubMed] [Google Scholar]
  23. Shiroky J. B., Neville C., Esdaile J. M., Choquette D., Zummer M., Hazeltine M., Bykerk V., Kanji M., St-Pierre A., Robidoux L. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1993 Jun;36(6):795–803. doi: 10.1002/art.1780360609. [DOI] [PubMed] [Google Scholar]
  24. Suzuki Y., Uehara R., Tajima C., Noguchi A., Ide M., Ichikawa Y., Mizushima Y. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol. 1999;28(5):273–281. doi: 10.1080/03009749950155454. [DOI] [PubMed] [Google Scholar]
  25. Weinblatt M. E., Maier A. L., Coblyn J. S. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol. 1993 Jun;20(6):950–952. [PubMed] [Google Scholar]
  26. Weinblatt M. E., Maier A. L., Fraser P. A., Coblyn J. S. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol. 1998 Feb;25(2):238–242. [PubMed] [Google Scholar]
  27. Wernick R., Smith D. L. Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum. 1989 Jun;32(6):770–775. doi: 10.1002/anr.1780320616. [DOI] [PubMed] [Google Scholar]
  28. Wolfe F., Cathey M. A. The effect of age on methotrexate efficacy and toxicity. J Rheumatol. 1991 Jul;18(7):973–977. [PubMed] [Google Scholar]
  29. van Ede A. E., Laan R. F., Rood M. J., Huizinga T. W., van de Laar M. A., van Denderen C. J., Westgeest T. A., Romme T. C., de Rooij D. J., Jacobs M. J. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001 Jul;44(7):1515–1524. doi: 10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  30. van Gestel A. M., Prevoo M. L., van 't Hof M. A., van Rijswijk M. H., van de Putte L. B., van Riel P. L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996 Jan;39(1):34–40. doi: 10.1002/art.1780390105. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES